Sanjay Sehgal, Ph.D.

Sanjay is the President & CEO of Aexelar Inc. Sanjay brings over 30 years of pharmaceutical industry experience from small, medium-sized, and multinational companies.

Dr. Sehgal’s core expertise includes regulatory strategy development, authoring and reviewing regulatory submissions, and negotiating approvals for new drug applications (NDAs). Sanjay has led the global regulatory strategy development, authored and reviewed multiple NDAs, and has successfully negotiated approvals for a dozen 505(B)(1) and 505(B)(2) NDAs encompassing chemistry, manufacturing, and controls (CMC), clinical and non-clinical sections along with multiple investigational new drug applications, IMPDs and CTAs while working at GlaxoSmithKline, TAP Pharmaceuticals (a division of Abbott Labs.), Procter & Gamble Pharmaceuticals, Wyeth Research, Gilead, Aprecia and Celularity.

Dr. Sehgal completed a Bachelor of Pharmacy degree in India and a Ph.D. in Pharmaceutics from the University of Alberta, Edmonton, Alberta, Canada. Sanjay was the Chair of Regulatory Sciences (RS) Section of the American Association of Pharmaceutical Scientists (AAPS) organization during 2007-08. He has chaired several symposia and roundtable discussions and has been an invited speaker at several AAPS, DIA, and international meetings.